Understanding how CD56 affects the growth and immune evasion of multiple myeloma
Investigating CD56 signaling in multiple myeloma growth and immune escape
['FUNDING_CAREER'] · OHIO STATE UNIVERSITY · NIH-10913375
This study is looking at a marker called CD56 in multiple myeloma to see how it helps the cancer grow and avoid treatment, with the goal of finding new ways to target it and improve treatment options for patients like you.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-10913375 on ClinicalTrials.gov |
What this research studies
This research investigates the role of a specific surface marker called CD56 in the growth and immune escape of multiple myeloma, a type of blood cancer. The study aims to understand how CD56 contributes to the cancer's resistance to treatments and its ability to evade the immune system. By exploring the mechanisms behind CD56's effects, the research seeks to develop new strategies to target and degrade this marker, potentially leading to better treatment options for patients. The findings could help tailor therapies specifically for multiple myeloma patients based on their unique disease characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with multiple myeloma, particularly those expressing the CD56 marker.
Not a fit: Patients with multiple myeloma who do not express the CD56 marker may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve outcomes for multiple myeloma patients.
How similar studies have performed: Other research has shown promise in targeting specific markers in cancers, suggesting that this approach could be effective, although the focus on CD56 in multiple myeloma is relatively novel.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COTTINI, FRANCESCA — OHIO STATE UNIVERSITY
- Study coordinator: COTTINI, FRANCESCA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers